FRONTIER BIOTECHNOLOGIES CO.Inc.

ABOUT US

 
HOME>About us

Frontier Biotech is a research-based, clinical stage pharmaceutical company utilizing cross-Pacific drug discovery and development business model. The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection and to be marketed in the near future. We are dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.

Our lead product candidate, Albuvirtide, is a treatment-paradigm shifting long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. An NDA was accepted by Chinese FDA in July 2016. Albuvirtide could become the first long-acting anti-HIV new drug worldwide.

Frontier Biotechnologies Inc.(Nanjing)

company headquarter, GMP manufacturing facility for peptide API and finished products

Frontier Biotech has established a highly-focused long-acting peptide drug discovery and development platform that could potentially transform any peptide drug into a long-acting agent. It could be used to discover new peptide drugs and/or develop long-acting peptide drugs from existing products. We welcome interested parties to contact us and discuss how this platform could be utilized to maximize the value of your products. With a core team of scientists dedicated in peptide synthesis (from mg to 100 kg), process development, analytical method development, CMC studies, GMP manufacturing for clinical supply, we also offer highly professional and value-added services.

Frontier Biotechnologies Inc.(Chongqing)

R&D and marketing.

Frontier Biotech has established a highly-focused long-acting peptide drug discovery and development platform that could potentially transform any peptide drug into a long-acting agent. It could be used to discover new peptide drugs and/or develop long-acting peptide drugs from existing products. We welcome interested parties to contact us and discuss how this platform could be utilized to maximize the value of your products. With a core team of scientists dedicated in peptide synthesis (from mg to 100 kg), process development, analytical method development, CMC studies, GMP manufacturing for clinical supply, we also offer highly professional and value-added services.

Frontier Biotechnologies Inc.(Beijing)

Center for clinical research, regulatory, government affairs, marketing and sales operation.

Frontier Biotech has established a highly-focused long-acting peptide drug discovery and development platform that could potentially transform any peptide drug into a long-acting agent. It could be used to discover new peptide drugs and/or develop long-acting peptide drugs from existing products. We welcome interested parties to contact us and discuss how this platform could be utilized to maximize the value of your products. With a core team of scientists dedicated in peptide synthesis (from mg to 100 kg), process development, analytical method development, CMC studies, GMP manufacturing for clinical supply, we also offer highly professional and value-added services.

TEAM

Dong Xie, Ph.D.

Founder, Chairman and Chief Scientific Officer

Prior to co-founding Frontier Biotech in 2002, Dr. Xie was Director of Research of Tibotec Inc., the US subsidiary of Tibotec NV (acquired by J&J in 2002). He was Head of Biophysics Laboratory at the NCI-Frederick Cancer Research and Development Center from 1995 to 2000, and Director of Operation of the Biocalorimetry Center at The Johns Hopkins University from 1993 to 1995. Dr. Xie received his B.S. degree in Physics from Peking University and Ph.D. degree in biophysics from The Johns Hopkins University.

CJ Wang, Ph.D.

Chief Executive Officer

With over 20 years technical and management experience in pharmaceutical and biotech industry in the US, Dr. Wang was vice president of business development of Vivus (a publically-traded pharmaceutical company, VVUS, NSDAQ), Abmaxis (acquired by Merck in 2006), and TaiGen Biotech; vice president of marketing and business development of Cellomics, and director of licensing and acquisition of Packard Biosciences (acquired by Perkin Elmer). Prior to holding business and management roles with increasing responsibilities, Dr. Wang was a principal scientist at Merck. Dr. Wang received his BS in Medical Science and MS in Medicinal Chemistry from Huaxi University of Medical Sciences, and Ph.D. in Pharmaceutical Sciences from College of Pharmacy, University of Kentucky.

Rongjian Lu, Ph.D.

Vice President, Chemistry

      Trained as a medicinal chemist, Dr. Lu has over 20 years drug discovery and development experience in both academic and industry laboratories. Prior to joining Frontier Biotech, Dr. Lu was a Principal Research Investigator at Sequoia, where he led projects in drug discovery and early development of hepatitis C virus NS3 protease inhibitors and PK enhancers. He has also held Principal Research Investigator and Project Manager positions at Trimeris Inc., and Research Scientist at Tibotec Inc., the US subsidiary of Tibotec NV (acquired by J&J in 2002). Dr. Lu has invented eight patents and published more than 48 papers. Dr. Lu received his Ph.D. in Organic Chemistry from Nankai University and held faculty position at Nankai University till early 1997. He had post-doctoral training at National Cancer Institute (NCI), Northeastern University and Harvard Medical School.

Develop innovative therapies to better human lives